Dihalogenated sulfanilamides and benzolamides are effective inhibitors of the three β-class carbonic anhydrases from Mycobacterium tuberculosis

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 28, Issue 2, 2013, Pages 384-387

  Maresca, Alfonso ^a   Scozzafava, Andrea ^a   Vullo, Daniela ^a   Supuran, Claudiu T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Carbonic anhydrase; Dihalogenated sulfanilamide benzolamide; Enzyme inhibitor; Mycobacterium tuberculosis; Sulfonamide; carbonic anhydrase

Indexed keywords

BENZOLAMIDE; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE INHIBITOR; ISOPROTEIN; SULFANILAMIDE DERIVATIVE;

ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; ENZYMOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MYCOBACTERIUM TUBERCULOSIS; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

BENZOLAMIDE; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; DOSE-RESPONSE RELATIONSHIP, DRUG; MOLECULAR STRUCTURE; MYCOBACTERIUM TUBERCULOSIS; PROTEIN ISOFORMS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFANILAMIDES;

EID: 84874626003     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2011.645539     Document Type: Article

References (28)

1. Suarez Covarrubias A, Larsson AM, Högbom M, Lindberg J, Bergfors T, Björkelid C et al. Structure and function of carbonic anhydrases from Mycobacterium tuberculosis. J Biol Chem 2005; 280: 18782-18789.
2. Covarrubias AS, Bergfors T, Jones TA, Högbom M. Structural mechanics of the pH-dependent activity of β-carbonic anhydrase from Mycobacterium tuberculosis. J Biol Chem 2006; 281: 4993-4999.
3. Minakuchi T, Nishimori I, Vullo D, Scozzafava A, Supuran CT. Molecular cloning, characterization, and inhibition studies of the Rv1284 β-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate. J Med Chem 2009; 52: 2226-2232.
4. Nishimori I, Minakuchi T, Vullo D, Scozzafava A, Innocenti A, Supuran CT. Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new β-carbonic anhydrase from Mycobacterium tuberculosis. J Med Chem 2009; 52: 3116-3120.
5. Güzel O, Maresca A, Scozzafava A, Salman A, Balaban AT, Supuran CT. Discovery of low nanomolar and subnanomolar inhibitors of the mycobacterial β-carbonic anhydrases Rv1284 and Rv3273. J Med Chem 2009; 52: 4063-4067.
6. Carta F, Maresca A, Covarrubias AS, Mowbray SL, Jones TA, Supuran CT. Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active β-carbonic anhydrase from Mycobacterium tuberculosisRv3588c. Bioorg Med Chem Lett 2009; 19: 6649-6654.
7. Nishimori I, Minakuchi T, Maresca A, Carta F, Scozzafava A, Supuran CT. The ß-carbonic anhydrases from Mycobacterium tuberculosis as drug targets. Curr Pharm Des 2010; 16: 3300-3309.
8. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008; 7: 168-181.
9. Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011; 10: 767-777.
10. Pastorekova S, Parkkila S, Pastorek J, Supuran CT. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem 2004; 19: 199-229.
11. Supuran CT. Carbonic anhydrase inhibitors and activators for novel therapeutic applications. Future Med Chem 2011; 3: 1165-1180.
12. Supuran CT. Bacterial carbonic anhydrases as drug targets: toward novel antibiotics? Front Pharmacol 2011; 2: 34.
13. Dye C. Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat Rev Microbiol 2009; 7: 81-87.
14. Furtado GH, Nicolau DP. Overview perspective of bacterial resistance. Expert Opin Ther Pat 2010; 20: 1273-1276.
15. Ginsberg AM. Emerging drugs for active tuberculosis. Semin Respir Crit Care Med 2008; 29: 552-559.
16. Showalter HD, Denny WA. A roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatment. Tuberculosis (Edinb) 2008; 88 Suppl 1: S3-17.
17. Tomioka H, Tatano Y, Yasumoto K, Shimizu T. Recent advances in antituberculous drug development and novel drug targets. Expert Rev Respir Med 2008; 2: 455-471.
18. Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003; 23: 146-189.
19. Winum JY, Köhler S, Supuran CT. Brucella carbonic anhydrases: new targets for designing anti-infective agents. Curr Pharm Des 2010; 16: 3310-3316.
20. Vullo D, Nishimori I, Minakuchi T, Scozzafava A, Supuran CT. Inhibition studies with anions and small molecules of two novel ß-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium. Bioorg Med Chem Lett 2011; 21: 3591-3595.
21. Nishimori I, Onishi S, Takeuchi H, Supuran CT. The α and β classes carbonic anhydrases from Helicobacter pylori as novel drug targets. Curr Pharm Des 2008; 14: 622-630.
22. Supuran CT. Carbonic anhydrase inhibition with natural products: novel chemotypes and inhibition mechanisms. Mol Divers 2011; 15: 305-316.
23. Supuran CT. Carbonic anhydrase inhibitors. Bioorg Med Chem Lett 2010; 20: 3467-3474.
24. Pacchiano F, Carta F, Vullo D, Scozzafava A, Supuran CT. Inhibition of ß-carbonic anhydrases with ureido-substituted benzenesulfonamides. Bioorg Med Chem Lett 2011; 21: 102-105.
25. Ilies MA, Vullo D, Pastorek J, Scozzafava A, Ilies M, Caproiu MT et al. Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives. J Med Chem 2003; 46: 2187-2196.
26. Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. J Biol Chem 1971; 246: 2561-2573.
27. Kolayli S, Karahalil F, Sahin H, Dincer B, Supuran CT. Characterization and inhibition studies of an ?-carbonic anhydrase from the endangered sturgeon species Acipenser gueldenstaedti. J Enzyme Inhib Med Chem 2011; 26: 895-900.
28. Schlicker C, Hall RA, Vullo D, Middelhaufe S, Gertz M, Supuran CT et al. Structure and inhibition of the CO2-sensing carbonic anhydrase Can2 from the pathogenic fungus Cryptococcus neoformans. J Mol Biol 2009; 385: 1207-1220.